Sam ALSFORD – London School of Hygiene & Tropical Medicine (Londres – Royaume Uni)
The development of high-throughput RNA interference screening technology in the protozoan parasite Trypanosoma brucei has enabled us to identify many of the parasite factors that contribute to the efficacy of the anti-trypanosomiasis drugs and to parasite sensitivity to the trypanolytic component of human serum. Our results have revealed unexpected interactions between these toxins and the pathways that they depend upon, giving insights into drug uptake, action and resistance mechanisms. More recently, we’ve been using this experimental system to identify the efficacy determinants of the drugs used against Leishmania, the related trypanosomatid responsible for leishmaniasis.
Site web du laboratoire : http://blogs.lshtm.ac.uk/alsfordlab/
Contact : Philippe Bastin (firstname.lastname@example.org – Poste 38.35)